Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 — Oct 2nd, 2024

Vera Therapeutics Two informational posters for ORIGIN Phase 3 and ORIGIN Extend trials of atacicept in IgAN accepted for presentation at Kidney Week; In-person and virtual R&D Day to discuss expanded atacicept R&D activities scheduled to take place in New York on October 2; BRISBANE, Ca...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Oct 4th, 2024

Vera Therapeutics BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 125,000 shares of Class A commo...

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024? — Sep 26th, 2024

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Vera Therapeutics Inc. (NASDAQ:VERA) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps The recent Fed rate cut has made the market cautio...

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases — Oct 2nd, 2024

Vera Therapeutics PIONEER study expands the investigation of atacicept into a broad definition of IgA nephropathy and into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; Multiple regulatory and clinical milestones expe...